Etcembly's TCR therapeutics featured in Forbes
AI expert and futurist Bernard Marr has written about Etcembly's innovative generative AI approach to developing TCR-based cancer...
Etcembly's TCR therapeutics featured in Forbes
Etcembly reveals world’s first AI generative bispecific T cell engager with picomolar affinity
Etcembly's T-cell engager featured in Inside Precision Medicine
Etcembly announces breakthrough in optimising TCR assets
Etcembly Appoints Scott Cuthill as Chief Business Officer
Research Complex at Harwell welcomes Etcembly
Etcembly establishes new lab & office space at Oxford Science Park
Zelluna Immunotherapy AS Announces Exclusive Research Collaboration with Etcembly Limited
Oxford-based machine learning start-up Etcembly secures Private Seed Funding